Benefits Outweigh Risks As Europe Okays Sanofi’s Zynquista, Despite Unresolved FDA CRL
As the US approval of Sanofi’s type 1 diabetes drug looks to be likely pushed back for another two years, EU approval means the drug can begin to gain market share on the other side of the Atlantic.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
The latest drug development news and highlights from our US FDA Performance Tracker.